SK Life Science sets up an indoor rainstorm to point to its anti-seizure drug Xcopri's full coverage
People who have seizures don’t just want relief, they want the seizures to stop, and SK Life Science is underscoring that desire with its “Half Way” campaign for Xcopri that is set to debut this weekend at the American Academy of Neurology’s annual meeting in Boston.
Playing on the status quo of a 50% reduction in seizures, the Xcopri booth will be half-covered by a giant umbrella while a simulated rainstorm rages. The onsite brand team will wear full-coverage purple rain gear to highlight the underlying message that Xcopri offers the possibility of zero seizures. In its studies, as many as one in five people had no seizures during the maintenance period. Xcopri was approved in 2019 to treat partial-onset seizures in adults.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
